| Literature DB >> 28803024 |
Keita Nakanishi1, Kandai Nozu2, Ryugo Hiramoto3, Shogo Minamikawa1, Tomohiko Yamamura1, Junya Fujimura1, Tomoko Horinouchi1, Takeshi Ninchoji1, Hiroshi Kaito1, Naoya Morisada1, Shingo Ishimori1, Koichi Nakanishi4, Ichiro Morioka1, Hiroyuki Awano1, Masafumi Matsuo5, Kazumoto Iijima1.
Abstract
Lowe syndrome is an X-linked inherited disorder diagnosed by congenital cataracts, intellectual impairment, and renal tubular dysfunction. It is caused by pathogenic variants of the oculocerebrorenal syndrome of Lowe gene (OCRL), of which more than 250 have been reported so far. Around 30 of these variants are intronic nucleotide changes; however, to show the pathogenicity of these variants is usually laborious. In this report, we conducted genetic testing of a patient clinically diagnosed with Lowe syndrome to detect the presence of OCRL variants. We analyzed variant transcript expression in peripheral blood leukocytes and using a minigene construct in addition to in silico analysis. We detected a 9 base pair intronic insertion between OCRL exon 10 and exon 11 derived from the alteration of the splicing acceptor site in intron 10 caused by the intronic splicing variant NM_000276.3: c.940-11G>A (p.Lys313_Val314insAsnSer*). The findings obtained from transcript analysis of peripheral blood leukocytes and the minigene construct assay were identical to those of in silico analysis. All assays detected the same transcript abnormality and were reliable in revealing the pathogenicity of the intronic variant. The in vitro assay can also be used to clarify the complicated splicing mechanisms in inherited kidney diseases.Entities:
Keywords: Lowe syndrome; Minigene; OCRL gene; Splicing assay
Mesh:
Substances:
Year: 2017 PMID: 28803024 DOI: 10.1016/j.ejmg.2017.08.001
Source DB: PubMed Journal: Eur J Med Genet ISSN: 1769-7212 Impact factor: 2.708